Forum Archive Index - September 2001

["G Stolwyk" <stolwyk@wave.co.nz>]

Readers, before proceeding, please read the Disclaimer in my previous post! 

---

 

Thank you, Colin!

 

I always appreciate a comment from a pharmacist!

 

There is a large market for anti-TNF pharmaceuticals now.

Below are comments from " Decision Resources, Inc." which reviews the commercial potential of novel agents in this field:

 

 The TNF-Alpha Inhibitors in therapeutic products: " Etanercept "( Immmunex/Wyeth-Ayerst's Enbrel ), " Infliximab " ( Centocor/ Johnson@ Johnson's Remicade ) being used in the rheumatoid arthritis ( RA ) and inflammatory bowel disease( IBD).

 

They predict that by 2010 approx. 37% of the anti-TNF market place will be attributed to sales in novel indications.

 

Psoriasis and Psoriatic Arthritis trials are now in late-stage clinical development  and the TNF inhibitor will be the principal driver of growth in this market according to forecasts.

 

Congestive Heart Failure ( CHF) This seems to be associated with high levels of TNF bio activity. This requires further study.

 

Sepsis: A modest but definite beneficial effect by application of a refined anti- TNF product " Afelimomab " ( Knoll/Abbott's Segard ) in an improved clinical trial design, have been noted.  

 

Yes, I have followed the TNF- Alpha Inhibitor market closely; it is showing great promise and profits are rising exponentially: It is a massive market! 

 

This post and the previous one were mainly written for this site:

 

http://www.ozestock.com.au/MessageBoard.asp?Action=ListBySymbol&Symbol=PTD

 

This is the prime Australian Message Board on PTD.

 

 I promised to do a summary of the status of PTD: See post 3241on that site.

 

( See also posts 340 and 1069 from the MMD Message Board).

 

There are some principal contributors there and they are nice people to work with: these traders are a team and act accordingly.

 

Gerry